Abstract
Inbred immunocompetent C57BL/6 mice have been a favored strain to study transgene expression of human blood coagulation factor IX (hF.IX) from viral vectors because systemic expression of the secreted protein is not limited by antibody responses following intravenous (i.v.) injection of vector. For example, i.v. injection of an adenoviral (Ad) vector results in sustained expression of hF.IX in normal or hemophilic C57BL/6 mice, while anti-hF.IX antibodies rapidly emerge in other strains (Gene Therapy 4: 473; Blood 91: 784). To investigate these observations further, we injected naive C57BL/6 mice and C57BL/6 mice with pre-existing anti-hF.IX with Ad-hF.IX vector via peripheral vein. All mice expressed hF.IX antigen without detectable anti-hF.IX, even when challenged with hF.IX in different immunogenic settings at later time points. Moreover, in mice with pre-existing immunity, anti-hF.IX titers diminished to undetectable levels after i.v. administration of Ad-hF.IX. Lymphocytes from mice that had received Ad-hF.IX i.v. failed to proliferate when stimulated with hF.IX in vitro after the animals had been repeatedly challenged with hF.IX protein formulated in complete Freund's adjuvant. Thus, absence of anti-hF.IX in C57BL/6 mice after i.v. injection of Ad vector is not due to ignorance to the foreign transgene product. Similar experiments in other strains showed that immune tolerance to hF.IX does not correlate with the strain haplotype or expression of IL-10 cytokine. Given the well-documented immunogenicity of the first-generation adenoviral vector, data from C57BL/6 mice may therefore grossly underestimate immunological consequences in certain gene therapy protocols.
Similar content being viewed by others
References
Hoyer LW . The incidence of factor VIII inhibitors in patients with severe hemophilia A Adv Exp Med Biol 1995 386: 35–46
High KA . Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation Adv Exp Med Biol 1995 386: 79–86
Herzog RW, High KA . AAV-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy Thr Haemost 1999 82: 540–546
Herzog RW, High KA . Problems and prospects in gene therapy for hemophilia Curr Opin Hematol 1998 5: 321–326
Kay MA et al. Evidence for gene transfer and expression of blood coagulation factor IX in patients with severe hemophilia B treated with an AAV vector Nat Genet 2000 24: 257–261
Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs Proc Natl Acad Sci USA 1994 91: 2353–2357
Lozier JN, Metzger ME, Donahue RE, Morgan RA . Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose limiting toxicity Blood 1999 94: 3968–3975
Smith TAG et al. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice Nat Genet 1994 5: 397–402
Fang B et al. Lack of persistence of E1− recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dog Gene Therapy 1996 3: 217–222
Connelly S et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy Blood 1996 88: 3846–3853
Walter J et al. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice Proc Natl Acad Sci USA 1996 93: 3056–3061
Kung J et al. Human F.IX corrects the bleeding diathesis of mice with hemophilia B Blood 1998 91: 784–790
Connelly S et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy Blood 1998 91: 3273–3281
Yang Y, Xiang Z, Ertl HCJ, Wilson JM . Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo Proc Natl Acad Sci USA 1995 92: 7257–7261
Yang Y et al. Immune response to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo Gene Therapy 1996 3: 137–144
Qian J, Bi L, Kazazian HH, Hoyer LW . Inhibitor development and T cell response to human factor VIII in murine hemophilia A Blood 1996 88 (Suppl. 1): 656a
Fields PA et al. Choice of vector determines T cell subsets involved in immune responses against the secreted transgene product factor IX Molec Ther 2000 1: 225–235
Herzog RW et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus Proc Natl Acad Sci USA 1997 94: 5804–5809
Murphy ML, Wille U, Hunter CA, Farrell JP . IL-10 deficient mice are resistant to Leishmania donovani infection FASEB J 1999 13: (Suppl. S) A655
Michou A et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression Gene Therapy 1997 4: 473–482
Vrancken Peeters M-JTFD, Lieber A, Perkins J, Kay MA . Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer BioTechniques 1996 20: 278–285
Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains Gene Therapy 1995 2: 151–155
Pastore L et al. Use of liver-specific promoter reduces immune response to the transgene in adenoviral vectors Hum Gene Ther 1999 10: 1773–1781
Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers J Virol 1998 72: 4212–4223
Waal Malefyt RD et al. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes J Exp Med 1991 174: 1209–1220
Groux H, Bigler M, Roncaralo MG . Interleukin 10 induces a long-term antigen-specific anergic state in human CD4+ T cells J Exp Med 1996 184: 19–29
Buer J et al. Interleukin-10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo J Exp Med 1998 187: 177–183
Knolle PA et al. Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells Hepatology 1998 27: 93–99
Loeser P, Jennings GS, Strauss M, Sandig V . Reactivation of the previously silenced cytomegalovirus major immediate–early promoter in the mouse liver: involvement of NFκB J Virol 1998 72: 180–190
Vemuru RP et al. Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation – implications for gene therapy FASEB J 1992 6: 2836–2842
Nakai H et al. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver Blood 1998 91: 4600–4607
Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors Nat Genet 1997 16: 270–276
Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors Nat Med 1999 5: 64–70
Nathwani A, Davidoff AM, Hanawa H, Nienhuis AW . The site of rAAV-mediated F.IX expression can significantly influence the level of expression and immunological response to the transgene product Mol Ther 2000 1: S287
Chao H, Mao L, Bruce AT, Walsh CE . Sustained expression of human factor VIII in mice using a parvovirus-based vector Blood 2000 95: 1594–1599
Balague C et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector Blood 2000 95: 820–828
Park F, Ohashi K, Kay MA . Therapeutic levels of human factor VIII and IX using HIV-based lentiviral vectors in mouse liver Blood 2000 96: 1173–1176
Brann T et al. Adenoviral vector-mediated expression of physiological levels of human factor VIII in non-human primates Hum Gene Ther 1999 10: 2999–3011
Park F et al. Efficient lentiviral transduction of liver requires cell cycling in vivo Nat Genet 2000 24: 49–52
Matsushita T . Adeno-associated virus vector can be efficiently produced without helper virus Gene Therapy 1998 5: 938–945
Matsushita T, Godwin S, Surosky R, Colosi P . Improvements in AAV vector production: elimination of pseudo-wild-type AAV Proc 2nd Ann Am Soc Gene Therapy. Washington, DC 1999 p 2a
Hagstrom JN et al. Enhanced muscle-derived expression of coagulation factor IX from a skeletal actin/CMV hybrid promoter Blood 2000 95: 2536–2542
Acknowledgements
This work was supported by NIH grant R01 HL61921 to KAH and NIH grant AI-27828 to JPF. PAF was supported by grants from the Medical Research Council (MRC, UK) and the Katherine Dormandy Trust for Hemophilia. RWH is supported by a Career Development Award from the National Hemophilia Foundation. The authors thank Dr Robert Coffman for providing the BALB/c IL-10 knock-out mice and Avigen, Inc., a company in which KAH holds equity, for providing AAV vector.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fields, P., Armstrong, E., Hagstrom, J. et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther 8, 354–361 (2001). https://doi.org/10.1038/sj.gt.3301409
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301409
- Springer Nature Limited
Keywords
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.